AMBER Data Support Green Light For Janssen's Symtuza
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.